134 related articles for article (PubMed ID: 30745584)
21. HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice.
Grillo F; Fassan M; Sarocchi F; Fiocca R; Mastracci L
World J Gastroenterol; 2016 Jul; 22(26):5879-87. PubMed ID: 27468182
[TBL] [Abstract][Full Text] [Related]
22. Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma.
van Hagen P; Biermann K; Boers JE; Stoss O; Sleddens HF; van Lanschot JJ; Dinjens WN; Rueschoff J; Wijnhoven BP
Dis Esophagus; 2015; 28(4):380-5. PubMed ID: 24611982
[TBL] [Abstract][Full Text] [Related]
23. [Dual-color silver-enhanced in-situ hybridization for determination of HER2 gene amplification in gastric carcinoma].
Fan D; Li Y; Ran W; Yu W; Li H
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):4-7. PubMed ID: 24713241
[TBL] [Abstract][Full Text] [Related]
24. Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction: rationale for the Belgian way of working.
Jouret-Mourin A; Hoorens A; De Hertogh G; Vanderveken J; Demetter P; Van Cutsem E
Acta Gastroenterol Belg; 2012 Mar; 75(1):9-13. PubMed ID: 22567741
[TBL] [Abstract][Full Text] [Related]
25. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
26. HER2 testing in gastric cancer.
Albarello L; Pecciarini L; Doglioni C
Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
[TBL] [Abstract][Full Text] [Related]
27. Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors.
Frati A; Chereau E; Coutant C; Bezu C; Antoine M; Chopier J; Daraï E; Uzan S; Gligorov J; Rouzier R
Breast Cancer Res Treat; 2012 Apr; 132(2):601-7. PubMed ID: 22160638
[TBL] [Abstract][Full Text] [Related]
28. HER2-low in gastro-oesophageal adenocarcinoma: a real-world pathological perspective.
Angerilli V; Parente P; Campora M; Ugolini C; Battista S; Cassoni P; Gambella A; Cavallin F; De Lisi G; Vanoli A; Grillo F; Mastracci L; Fassan M
J Clin Pathol; 2023 Dec; 76(12):815-821. PubMed ID: 37055161
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
30. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
31. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas.
Fassan M; Ludwig K; Pizzi M; Castoro C; Guzzardo V; Balistreri M; Zaninotto G; Ruol A; Giacomelli L; Ancona E; Rugge M
Hum Pathol; 2012 Aug; 43(8):1206-12. PubMed ID: 22217477
[TBL] [Abstract][Full Text] [Related]
32. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
[TBL] [Abstract][Full Text] [Related]
33. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
Fujii T; Kogawa T; Wu J; Sahin AA; Liu DD; Chavez-MacGregor M; Giordano SH; Raghavendra A; Murthy RK; Tripathy D; Shen Y; Yamal JM; Ueno NT
Br J Cancer; 2017 Feb; 116(4):509-514. PubMed ID: 28081544
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
[TBL] [Abstract][Full Text] [Related]
35. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF; Polydorides AD
Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
[TBL] [Abstract][Full Text] [Related]
36. HER2 testing in gastric cancer: An update.
Abrahao-Machado LF; Scapulatempo-Neto C
World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694
[TBL] [Abstract][Full Text] [Related]
37. A study of HER2 gene amplification and protein expression in gastric cancer.
Yan B; Yau EX; Bte Omar SS; Ong CW; Pang B; Yeoh KG; Salto-Tellez M
J Clin Pathol; 2010 Sep; 63(9):839-42. PubMed ID: 20696687
[TBL] [Abstract][Full Text] [Related]
38. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
Nadaf AS; Rani H; Dinesh US
Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
[TBL] [Abstract][Full Text] [Related]
39. Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study.
Watson S; Validire P; Cervera P; Zorkani N; Scriva A; Lemay F; Tournigand C; Perniceni T; Garcia ML; Bennamoun M; Paye F; Louvet C
Ann Oncol; 2013 Dec; 24(12):3035-9. PubMed ID: 24114855
[TBL] [Abstract][Full Text] [Related]
40. Dual-Energy CT-Based Nomogram for Decoding HER2 Status in Patients With Gastric Cancer.
Zhao H; Li W; Huang W; Yang Y; Shen W; Liang P; Gao J
AJR Am J Roentgenol; 2021 Jun; 216(6):1539-1548. PubMed ID: 33852330
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
